Press Release
Category Added in a WPeMatico Campaign
-
Business Wire11 February 2026
GCT Semiconductor Partners with Skylo to Accelerate Global Satellite Connectivity
The companies are collaborating to expand seamless global satellite connectivity for next-generation cellular IoT devices, including joint efforts towards chip…
Read More » -
Business Wire11 February 2026
Ryder Reports Fourth Quarter 2025 Results and Provides 2026 Outlook
Transformed Business Model Continues to Outperform Prior Cycles; Upsized Strategic Initiatives Expected to Drive 2026 Earnings Growth Fourth Quarter 2025…
Read More » -
Business Wire11 February 2026
AECOM to provide detailed design services to support delivery of Sydney Metro West
DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced it will deliver detailed design services for the Sydney…
Read More » -
Business Wire11 February 2026
CHIMERA INVESTMENT CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2025 EARNINGS
NEW YORK–(BUSINESS WIRE)–Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the fourth quarter and full year ended December…
Read More » -
Business Wire11 February 2026
Ferguson to Issue Results for the Period Ended December 31, 2025, as well as provide an Update on Market Opportunities and Strategy on February 24, 2026
NEWPORT NEWS, Va.–(BUSINESS WIRE)–Ferguson Enterprises Inc. (NYSE: FERG; LSE: FERG) announces today that it will issue its results for the…
Read More » -
Business Wire11 February 2026
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube…
Read More » -
Business Wire11 February 2026
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent Technologies Inc.…
Read More » -
Business Wire11 February 2026
Chimera Increases First Quarter 2026 Common Stock Dividend to $0.45 and Declares First Quarter 2026 Preferred Stock Dividends
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.45 PER SHARE OF COMMON STOCK BOARD EXPECTS CHIMERA TO MAINTAIN A QUARTERLY…
Read More » -
Cision PR Newswire11 February 2026
BorgWarner Reports 2025 Results and Provides 2026 Guidance; Returned Approximately $630 Million to Shareholders in 2025; Strategically Enters Data Center Market with Turbine Generator System Award
AUBURN HILLS, Mich., Feb. 11, 2026 /PRNewswire/ — BorgWarner Inc. (NYSE: BWA) today reported fourth quarter and full-year 2025 results…
Read More » -
Cision PR Newswire11 February 2026
CGI positioned as Leader in 2026 Gartner® Magic Quadrant™ for Banking Payment Hub Platforms
Stock Market Symbols GIB.A (TSX) GIB (NYSE) cgi.com/newsroom MONTRÉAL, Feb. 11, 2026 /PRNewswire/ – CGI Inc. (NYSE: GIB) (TSX: GIB.A),…
Read More »